topiramate and Muscle-Weakness

topiramate has been researched along with Muscle-Weakness* in 2 studies

Other Studies

2 other study(ies) available for topiramate and Muscle-Weakness

ArticleYear
Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency.
    BMC neurology, 2021, Feb-27, Volume: 21, Issue:1

    Multiple acyl-CoA dehydrogenase deficiency (MADD) is a treatable lipid metabolism disorder that presents as myopathy and episodic metabolic crisis. The metabolic crisis is typically associated with prolonged fasting or physical stress; however, the mechanism of metabolic crisis is not yet fully understood.. A 28-year-old Taiwanese woman presented with dyspnoea, poor appetite, and muscle weakness after using antiobesity drugs, including metformin, triiodothyronine, and topiramate. MADD was diagnosed, and her symptoms rapidly improved after treatment with riboflavin, carnitine, and ubiquinone. To date, antiobesity drugs have not been reported to be a provoking factor in fatty acid oxidation disorder.. The increase of β-oxidation activity due to antiobesity drugs supports the hypothetical substrate competition model for MADD metabolic crisis. Because the drugs our patient used are commonly prescribed, we report this case to increase the vigilance and proactivity of clinicians in recognising this treatable adult-onset myopathy.

    Topics: Adult; Anti-Obesity Agents; Asian People; Carnitine; Female; Humans; Metformin; Multiple Acyl Coenzyme A Dehydrogenase Deficiency; Muscle Weakness; Muscular Diseases; Riboflavin; Topiramate; Triiodothyronine; Ubiquinone

2021
Treatment of hypokalemic periodic paralysis with topiramate.
    Muscle & nerve, 2011, Volume: 43, Issue:1

    Hypokalemic periodic paralysis (hypoPP), the most common form of periodic paralysis, is a disorder characterized by attacks of transient muscle weakness associated with a drop in serum potassium level.The mainstay of treatment is potassium supplementation and drugs that inhibit the enzyme carbonic anhydrase. In this report we describe 11-year-old twins with hypoPP who were treated with topiramate, an anti-epileptic drug known to have carbonic anhydrase inhibitory properties. The patients experienced a decrease in the severity of their attacks upon initiation of treatment. Topiramate may warrant further investigation as a treatment option in hypoPP.

    Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Child; Fructose; Humans; Hypokalemic Periodic Paralysis; Male; Muscle Weakness; Muscle, Skeletal; Neuroprotective Agents; Potassium Deficiency; Topiramate; Treatment Outcome

2011